Cord Blood News Volume 4.45 | Nov 15 2012

Inhibition of T Cell Protein Tyrosine Phosphatase (TC-PTP) Enhances IL-18-Dependent Hematopoietic Stem Cell Expansion
Researchers reported that inhibition of TC-PTP, an enzyme involved in the regulation of cytokine signaling, through gene knockout results in a 9-fold increase in the number of hematopoietic progenitors in murine bone marrow (BM). This effect could be reproduced using a short treatment with a pharmacological inhibitor of TC-PTP in murine BM, as well as in human BM, peripheral blood and cord blood. [Stem Cells]
Abstract | Full Article

Proteasome Inhibition Upregulates Bim and Induces Caspase-3-Dependent Apoptosis in Human Mast Cells Expressing the Kit D816V Mutation
The authors investigated here whether prevention of Bim degradation by a proteasomal inhibitor, MG132, would induce apoptosis in mast cells with the D816V mutation. Human umbilical cord blood-derived mast cells with wild-type Kit and two different subclones of the human mast cell line-1 were used for the study. [Cell Death Dis] Full Article

Rapid T-Cell Chimerism Switch and Memory T-Cell Expansion Are Associated with Pre-Engraftment Immune Reaction Early after Cord Blood Transplantation
Scientists reported the engraftment kinetics of donor-derived T cells using a multicolor flow cytometry-based method and also described the results of naïve/memory T-cell phenotype analyses early after cord blood transplantation. [Br J Haematol] Full Article

Characterization of a Distinct Population of Circulating Human Non-Adherent Endothelial Forming Cells and Their Recruitment via Intercellular Adhesion Molecule-3
Investigators isolated, enriched for and then characterized a human umbilical cord blood derived CD133⁺ population of non-adherent endothelial forming cells which expressed the hematopoietic progenitor cell markers together with mature endothelial cell markers. [PLoS One] Full Article

Pdx1 and Controlled Culture Conditions Induced Differentiation of Human Amniotic Fluid-Derived Stem Cells to Insulin-Producing Clusters
Scientists investigated the differentiation of human amniotic fluid-derived stem cells into insulin-producing clusters in vitro. [J Tissue Eng Regen Med] Abstract

Use of Poly(DL-Lactide-ε-Caprolactone) Membranes and Mesenchymal Stem Cells from the Wharton’s Jelly of the Umbilical Cord for Promoting Nerve Regeneration in Axonotmesis: In Vitro and In Vivo Analysis
Researchers evaluated the therapeutic value of human umbilical cord matrix mesenchymal stem cells on rat sciatic nerve after axonotmesis injury associated to Vivosorb® membrane. [Differentiation] Abstract

Generation of Induced Pluripotent Stem Cells from Human Amniotic Fluid Cells by Reprogramming with Two Factors in Feeder-Free Conditions
Investigators showed that induced pluripotent stem cells can be generated from human amniotic fluid cells with two transcription factors: OCT4 and KLF4. [J Reprod Dev] Abstract

MicroRNAs as Markers for Neurally Committed CD133+/CD34+ Stem Cells Derived from Human Umbilical Cord Blood
Neural differentiation of the CD133+/CD34+ subpopulation of human umbilical cord blood stem cells was investigated, and neuro-microRNA expression was examined. [Biochem Genet] Abstract | Full Article

First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at Duke University
Gamida Cell Ltd. announced that the first patient, enrolled in its pilot study of NiCord^® as an investigational treatment for sickle cell disease, has been transplanted at Duke University in North Carolina. NiCord^® is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. [Gamida Cell Ltd.] Press Release

Ontario Genomics Institute Invests in Stem Cell Technology at Tissue Regeneration Therapeutics
The Ontario Genomics Institute has invested in Toronto-based Tissue Regeneration Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells to treat a variety of serious medical conditions. TRT will use this investment to conduct studies required to apply for approval to initiate human clinical trials. [Ontario Genomics Institute] Press Release

China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
China Cord Blood Corporation (CCBC) announced the successful completion of the transaction with Cordlife Group Limited. As a result of the transaction, CCBC now wholly owns the equity ownership of Guangzhou Municipality Tianhe Nuoya Bio-engineering Co. Ltd. and Cordlife acquired 7,314,015 ordinary shares of the Company, representing approximately 10% of the Company’s issued and outstanding shares. [China Cord Blood Corporation] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Research Associate in Stem Cell Biology – Cardiovascular Regeneration (CReATe Fertility Centre)

Senior Research Technologist – Hematology (St. Jude Children’s Research Hospital)

Postdoctoral Fellow in Stem Cell Biology (University of Texas Medical School at Houston)

Senior Research Fellowships (Josep Carreras Leukaemia Research Institute)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.